Arrowhead Pharmaceuticals Stock In The News

ARWR Stock  USD 18.79  0.25  1.35%   
Our overall analysis of Arrowhead Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Arrowhead Pharmaceuticals. The specific impact of Arrowhead Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Arrowhead Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Arrowhead Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Arrowhead Pharmaceuticals Backtesting and Arrowhead Pharmaceuticals Hype Analysis.
To learn how to invest in Arrowhead Stock, please use our How to Invest in Arrowhead Pharmaceuticals guide.

Arrowhead Pharmaceuticals Today Top News and Investor Outlook

Yahoo News
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/arrowhead-pharmaceuticals-reports-inducement-grants-203000632.html
 Bullish
Yahoo News
With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners
https://finance.yahoo.com/news/73-ownership-shares-arrowhead-pharmaceuticals-160134150.html
 Bullish
Yahoo News
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
https://finance.yahoo.com/news/arrowhead-pharmaceuticals-files-regulatory-clearance-113000840.html
 Bullish
Yahoo News
ARWR: PALISADE Phase 3 Results Published in NEJM…
https://finance.yahoo.com/news/arwr-palisade-phase-3-results-150100395.html
 Neutral
Yahoo News
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
https://finance.yahoo.com/news/arrowhead-pharmaceuticals-receives-fda-breakthrough-113000493.html
 Neutral
Yahoo News
Arrowhead Pharmaceuticals Presents New P...
https://finance.yahoo.com/news/arrowhead-pharmaceuticals-presents-pivotal-phase-103600472.html
 Neutral
Yahoo News
ARWR: Two Obesity Assets to Enter the Clinic in 2025…
https://finance.yahoo.com/news/arwr-two-obesity-assets-enter-135800284.html
 Neutral
Yahoo News
Arrowhead Pharmaceuticals to Present New...
https://finance.yahoo.com/news/arrowhead-pharmaceuticals-present-phase-3-113000911.html
 Neutral
Yahoo News
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
https://finance.yahoo.com/news/arrowhead-pharmaceuticals-advance-two-rnai-173000630.html
 Bullish
Yahoo News
Arrowhead Research: Fiscal Q3 Earnings Snapshot
https://finance.yahoo.com/news/arrowhead-research-fiscal-q3-earnings-203742557.html
 Neutral

Arrowhead Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Arrowhead and other traded companies coverage with news coverage. We help investors stay connected with Arrowhead headlines for the 25th of November to make an informed investment decision based on correlating the impacts of news items on Arrowhead Stock performance. Please note that trading solely based on the Arrowhead Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Arrowhead Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Arrowhead Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Arrowhead Pharmaceuticals noise-free hype analysis.
Arrowhead Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Arrowhead earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Arrowhead Pharmaceuticals that are available to investors today. That information is available publicly through Arrowhead media outlets and privately through word of mouth or via Arrowhead internal channels. However, regardless of the origin, that massive amount of Arrowhead data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arrowhead Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arrowhead Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arrowhead Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arrowhead Pharmaceuticals alpha.

Arrowhead Largest EPS Surprises

Earnings surprises can significantly impact Arrowhead Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-02-05
2019-12-31-0.01-0.03-0.02200 
2018-02-09
2017-12-31-0.16-0.18-0.0212 
2017-02-06
2016-12-31-0.2-0.170.0315 
2017-05-03
2017-03-31-0.12-0.080.0433 
2019-11-25
2019-09-300.160.11-0.0531 
2019-05-08
2019-03-310.190.240.0526 
View All Earnings Estimates

Arrowhead Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Arrowhead Pharmaceuticals Stock. Current markets are strongly bullish. About 75% of major world exchanges and indexes are currently up. See today's market update for more information.
businesswire News
18th of November 2024
Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-...
at businesswire.com 
news
13th of November 2024
Arrowhead Pharmaceuticals Upgraded at StockNews.com
at thelincolnianonline.com 
Simply Wall St News at Macroaxis
1st of November 2024
In the wake of Arrowhead Pharmaceuticals, Inc.s latest US108m market cap drop, institution...
at simplywall.st 
businesswire News
14th of October 2024
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635
at businesswire.com 
Simply Wall St News at Macroaxis
4th of October 2024
Is Arrowhead Pharmaceuticals A Risky Investment
at simplywall.st 
businesswire News
23rd of September 2024
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 12a Study of AR...
at businesswire.com 
news
17th of September 2024
Arrowhead Pharmaceuticals, Inc. Sees Significant Decline in Short Interest
at thelincolnianonline.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arrowhead Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arrowhead Pharmaceuticals' short interest history, or implied volatility extrapolated from Arrowhead Pharmaceuticals options trading.

Additional Tools for Arrowhead Stock Analysis

When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.